NCT04385849View on ClinicalTrials.gov

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

PHASE1TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

July 25, 2020

Study Completion Date

July 25, 2020

Conditions

COVID-19

Interventions

BIOLOGICAL

N-803

Recombinant human super agonist interleukin-15 (IL-15) complex

OTHER

Saline

Sterile saline solution

Trial Locations (1)

90262

St. Francis, Lynwood

Sponsors

Lead Sponsor

ImmunityBio, Inc.

All Listed Sponsors

lead

ImmunityBio, Inc.

INDUSTRY

NCT04385849 - Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 | Biotech Hunter | Biotech Hunter